319
Participants
Start Date
June 1, 2023
Primary Completion Date
September 24, 2024
Study Completion Date
September 24, 2024
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
Standard Therapy plus continuous glucose monitoring (CGM)
Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
Icahn School of Medicine at Mt. Sinai, New York
SUNY Upstate Medical University, Syracuse
University of Pennsylvania, Philadelphia
Baltimore VA Medical Center, Baltimore
University of Virginia, Charlottesville
Emory University School of Medicine, Atlanta
UHH Cleveland Medical Center, Cleveland
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
Northwestern University, Chicago
University of Texas Southwestern, Dallas
Texas Diabetes and Endocrinology, P.A., Austin
Rocky Mountain Clinical Research, Idaho Falls
Diabetes & Endocrine Treatment Specialists, Sandy City
Hoag Memorial Hospital Presbyterian, Newport Beach
Oregon Health & Science University, Portland
Rainier Clinical Research Center, Renton
University of Washington, Seattle
Boston Medical Center Corporation, Boston
Lawson Health Research Institute, London
McGill University, Montreal
Collaborators (1)
Jaeb Center for Health Research
OTHER
Tandem Diabetes Care, Inc.
INDUSTRY